Company intelligence / Profile preview

Actio Biosciences

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

Actio Biosciences is advancing two first-in-class, orally available small molecule inhibitors: ABS-0871 (TRPV4 inhibitor) in Phase 1 for CMT2C/overactive bladder and ABS-1230 (KCNT1 inhibitor) entering Phase 1 in 2025 for KCNT1-related epilepsies. Both have received orphan/rare pediatric drug designations from FDA; preclinical models show marked benefit, and clinical results pending.

Therapeutic areas: UrologyNeurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Investors include Regeneron VenturesDeerfield ManagementCanaanDroia VenturesEuclidean Capitalno public pharma co-development/marketing partners announced

Beyond the preview

Go deeper on Actio Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Actio Biosciences.

Explore the full profile